The role of tissue microarray in the era of target-based agents

Expert Review of Anticancer Therapy

Volumn 11, Issue 6, 2011, Pages 859-869

  Franco, Renato ^a   Caraglia, Michele ^b   Facchini, Gaetano ^a   Abbruzzese, Alberto ^b   Botti, Gerardo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

fluorescence in situ hybridization; immunohistochemistry; multiple biomarker TMA; prognostic TMA; tissue microarrays; TMA classification

Indexed keywords

BEVACIZUMAB; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN E; EPSTEIN BARR VIRUS ENCODED RNA; IMATINIB; INTERFERON REGULATORY FACTOR 4; PROTEIN BCL 6; RETINOBLASTOMA PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2; TAMOXIFEN; TRANSCRIPTION FACTOR EZH2; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; VIRUS RNA;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOANALYSIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER SCREENING; CANCER THERAPY; CANCER TISSUE; CHEMORADIOTHERAPY; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DATA ANALYSIS; DIAGNOSTIC ACCURACY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOLECULARLY TARGETED THERAPY; NEEDLE BIOPSY; PROGNOSIS; STATISTICAL ANALYSIS; TISSUE MICROARRAY; TUMOR GROWTH; UTERINE CERVIX CANCER;

CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79959782635     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.65     Document Type: Article

References (69)

1. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 291, 1304-1351 (2001 (Pubitemid 32173090)
2. Shergill IS, Freeman A, Mundy AR. Tissue microarrays in urology. BJU 94, 22-25 (2004 (Pubitemid 38980303)
3. Shergill IS, Rao AR, Anjum FH et al. Tissue microarrays and their relevance to the urologist. J. Urol. 175, 19-16 (2006
4. Tzankov A, Went P, Zimpfer A, Dirnhofer S. Tissue microarray technology: principles, pitfalls and perspectives - lessons learned from hematological malignancies. Exp. Gerontol. 40, 737-744 (2005 (Pubitemid 41265824)
5. Went PT, Dirnhofer S, Bundi M et al. Prevalence of KIT expression in human tumours. J. Clin. Oncol. 22, 4514-4522 (2004 (Pubitemid 41185118)
6. Kambham N, Kong C, Longacre TA. Utility of syndecan-1 (CD138) expression in the diagnosis of undifferentiated malignant neoplasms: a tissue microarray study of 1,754 cases. Appl. Immunohistochem. Mol. Morphol. 13, 304-310 (2005 (Pubitemid 41697391)
7. Mhawech-Fauceglia P, Herrmann F, Bshara W. FLI-1 expression in 4323 malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody. J. Clin. Pathol. 60(6), 694-700 (2006 (Pubitemid 46975228)
8. Cantile M, Franco R, Tschan A et al. HOX D13 expression across 79 tumour tissue types. Int. J. Cancer 125(7), 1532-1541 (2009
9. Nocito A, Kononen J, Kallioniemi OP et al. Tissue microarrays for high-throughput molecular pathology research. Int. J. Cancer 94(1), 1-5 (2001 (Pubitemid 32801745)
10. Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629 (2002
11. Bubendorf L, Kolmer M, Kononen J et al. Hormone therapy failure in human prostate cancer analysis by complementary DNA and tissue microarrays. J. Natl Cancer Inst. 91, 1758-1764 (1999 (Pubitemid 29518772)
12. Moch H, Schraml P, Bubendorf L et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am. J. Pathol. 154, 981-986 (1999 (Pubitemid 29169731)
13. Richter J, Wagner U, Kononen J et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am. J. Pathol. 157, 787-794 (2000 (Pubitemid 32109371)
14. Ronald S, Martina M, Guido S. Tissue microarrays for early target evaluation. Drug Discov. Today Technol. 1, 41-48 (2004)
15. Sapino A, Marchió C, Senetta R et al. Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch. 449(3), 288-296 (2006 (Pubitemid 44367968)
16. Chung JY, Braunschweig T, Hewitt SM. Optimization of recovery of RNA from formalin-fixed, paraffin-embedded tissue. Diagn. Mol. Pathol. 15, 229-236 (2006 (Pubitemid 44813662)
17. Prieto DA, Hood BL, Darfler MM et al. Liquid tissue: proteomic profiling of formalin-fixed tissues. Biotechniques 38(Suppl.), 32-35 (2005
18. Sauter G, Simon R, Hillan K. Tissue microarrays in drug discovery. Nat. Rev. Drug. Discov. 2, 962-972 (2003 (Pubitemid 37540578)
19. Went TH, Dirnhofer S, Bundi M et al. Prevalence of KIT expression in human tumors. J. Clin. Oncol. 22, 4514-4522 (2004 (Pubitemid 41185118)
20. Coffey J, Linger R, Pugh J et al. Somatic KIT mutations occur predominantly in seminoma germ cell tumours and are not predictive of bilateral disease: report of 220 tumours and review of literature. Genes Chromosomes Cancer 47(1), 34-42 (2008 (Pubitemid 350191462)
21. Vila L, Liu H, Al-Quran SZ et al. Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. Mod. Pathol. 22(10), 1296-1302 (2009
22. Torres-Cabala CA, Wang WL, Trent J et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod. Pathol. 22(11), 1446-1456 (2009
23. Schraml P, Kononen J, Bubendorf L et al. Tissue microarrays for gene amplification surveys in many different tumour types. Clin. Cancer Res. 5(8), 1966-1975 (1999 (Pubitemid 29399245)
24. Marx AH, Tharun L, Muth J et al. HER-2 amplification is highly homogenous in gastric cancer. Hum. Pathol. 40(6), 769-777 (2009
25. Liu S, Chia SK, Mehl E et al. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res. Treat. 119(1), 53-61 (2010
26. Zhu H, Pei HP, Zeng S et al. Profiling protein markers associated with the sensitivity to concurrent chemoradiotherapy in human cervical carcinoma. J. Proteome Res. 8(8), 3969-3976 (2009
27. McCarthy F, Fletcher A, Dennis N et al. An improved method for constructing tissue microarrays from prostate needle biopsy specimens. J. Clin. Pathol. 62(8), 694-698 (2009
28. Fejzo MS, Slamon DJ. Frozen tumour tissue microarray technology for analysis of tumour RNA, DNA, and proteins. Am. J. Pathol. 159, 1645-1650 (2001 (Pubitemid 33062507)
29. Moskaluk CA, Stoler MH. Agarose mold embedding of cultured cells for tissue microarrays. Diagn. Mol. Pathol. 11, 234-238 (2002 (Pubitemid 35364939)
30. Voduc D, Kenney C, Nielsen TO. Tissue microarrays in clinical oncology. Semin. Radiat. Oncol. 18(2), 89-97 (2008 (Pubitemid 351296453)
31. Hassan S, Ferrario C, Mamo A et al. Tissue micro array: emerging standard for biomarker validation. Curr. Opin. Biotechnol. 19(1), 19-25 (2008 (Pubitemid 351226513)
32. Jubb AM, Hurwitz HI, Bai W et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol. 24, 217-227 (2006 (Pubitemid 46622051)
33. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab. Invest. 80, 1943-1949 (2000). (Pubitemid 32012762)
34. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J. Clin. Oncol. 26(34), 5630-5637 (2008
35. Hoos A, Urist MJ, Stojadinovic A et al. Validation of tissue microarray for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am. J. Pathol. 158(4), 1245-1251 (2001 (Pubitemid 32281288)
36. Pepe MS. Evaluating technologies for classification and prediction in medicine Stat. Med. 24(24), 3687-3696 (2005 (Pubitemid 43115725)
37. Tzankov A, Zimpfer A, Pehrs AC et al. Expression of B-cell markers in classical Hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod. Pathol. 16(11), 1141-1147 (2003 (Pubitemid 37414209)
38. Garcia JF, Camacho FI, Morente M et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumour suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 101(2), 681-689 (2003 (Pubitemid 36077593)
39. Rubin MA, Dunn R, Strawderman M, Pienta KJ. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am. J. Surg. Pathol. 26, 312-319 (2002 (Pubitemid 34184454)
40. Franco R, Camacho F, Caleo A et al. Nuclear bcl10 expression characterizes a group of ocular adnexa MALT lymphomas with shorter failure-free survival. Mod. Pathol. 19(8), 1055-1067 (2006 (Pubitemid 44106721)
41. Sugimura H, Mori H, Nagura K et al. FISH analysis with a TMA: 'fish and chips' analysis of pathology archives. Pathol. Int. 60, 543-550 (2010
42. Brown LA, Huntsman D. Fluorescent in situ hybridization on tissue microarrays: challenges and solutions. J. Mol. Histol. 38,151-157 (2007 (Pubitemid 46659334)
43. McCabe A, Dolled-Filhart M, Camp RL et al. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J. Natl Cancer Inst. 97, 1808-1815 (2005 (Pubitemid 43033901)
44. Camp RL, Dolled-Filhart M, King BL et al. Quantitative analysis of breast cancer tissue microarrays Cancer Res. 63, 1445-1448 (2003
45. McShane LM, Altman DG, Sauerbrei W et al. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARKJ. Natl Cancer Inst. 97, 1180-1184 (2005 (Pubitemid 41258223)
46. Altman DG, Lausen B, Sauerbrei W et al. Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J. Natl Cancer Inst. 86, 829-835 (1994 (Pubitemid 2100935)
47. Clark TG, Bradburn MJ, Love SB et al. Survival analysis part IV: further concepts and methods in survival analysis. Br. J. Cancer 89, 781-786 (2003 (Pubitemid 37175795)
48. Mallett S, Timmer A, Sauerbrei W et al. Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. Br. J. Cancer 102(1), 173-180 (2010
49. Zerkowsky MP, Camp RL, Burtness BA et al. Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome. Cancer Invest. 25, 19-26 (2007 (Pubitemid 46423585)
50. Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J. Clin. Pathol. 60, 1112-1116 (2007 (Pubitemid 47612643)
51. Rhodes DR, Sanda MG, Otte AP et al. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J. Natl Cancer Inst. 95, 661-668 (2003 (Pubitemid 36603722)
52. Kim HL, Seligson D, Liu X et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin. Cancer Res. 10, 5464-5471 (2004 (Pubitemid 39100484)
53. Saez AI, Saez AJ, Artiga MJ et al. Building an outcome predictor model for diffuse large B-cell lymphoma. Am. J. Pathol. 164, 613-622 (2004
54. Alonso SR, Ortiz P, Pollan M et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles a tissue microarray-based study. Am. J. Pathol. 164, 193-203 (2004 (Pubitemid 38364604)
55. Jacquemier J, Ginestier C, Rougemont J et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res. 65(3), 767-779 (2005 (Pubitemid 40216434)
56. Alkushi A, Irving J, Hsu F et al. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch. 442(3), 271-277 (2003 (Pubitemid 36399222)
57. Alkushi A, Clarke BA, Akbari M et al. Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod. Pathol. 20(11), 1156-1165 (2007 (Pubitemid 47609063)
58. Schwartz EJ, Molina-Kirsch H, Zhao S et al. Immunohistochemical characterization of nasal-type extranodal NK/T-cell lymphoma using a tissue microarray: an analysis of 84 cases. Am. J. Clin. Pathol. 130(3), 343-351 (2008
59. Gamal G, Sano T, Sakurai S et al. Immunohistopathological re-evaluation of adenocarcinoma of the lung with mixed subtypes using a tissue microarray technique and hierarchical clustering analysis. Pathol. Int. 57(12), 765-774 (2007 (Pubitemid 350060599)
60. Salto-Tellez M, Nga ME, Han HC et al. Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours. Br. J. Cancer 96, 776-782 (2007 (Pubitemid 46376613)
61. Makretsov NA, Huntsman DG, Nielsen TO et al. Hierachical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin. Cancer Res. 10, 6143-6151 (2004 (Pubitemid 39287520)
62. Simon R, Mirlacher M, Sauter G. Tissue microarrays. Biotechniques 36(1), 98-105 (2004 (Pubitemid 38076386)
63. Shi T, Seligson D, Belldegrun AS, Palotie A, Horvath S. Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma. Mod. Pathol. 18, 547-557 (2005 (Pubitemid 40478119)
64. Giltnane JM, Rimm DL. Technology insight: identification of biomarkers with tissue microarray technology. Nat. Clin. Pract. Oncol. 1, 104-111 (2004). (Pubitemid 40823750)
65. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat. Med. 8(11), 1323-1327 (2002 (Pubitemid 35373567)
66. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001 (Pubitemid 32165345)
67. Watson R. Euro MPs threaten UK stem cell research. BMJ 326, 838 (2003
68. Nishizuka S, Chen S, Gwadry FG et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res. 63, 5243-5250 (2003 (Pubitemid 37139837)
69. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for highthroughput molecular profiling of tumour specimens. Nat. Med. 4, 844-847 (1998). (Pubitemid 28331029)